Selank Review: Mechanism of Action, Use Safety, Intended Uses, Differences between Selank & Semax, FAQs

Selank is an intranasal heptapeptide that has a defined clinical history in Russia and a growing preclinical literature. It was developed as a tuftsin-derived peptide optimized for central nervous system activity and is marketed as an anxiolytic with nootropic features, which makes it relevant for studies that link stress regulation with cognition. Based on available human and animal data, Selank is most often discussed in the context of:

This article reviews what Selank is, how it was developed, and what has been reported about its main effects in clinical and experimental settings. 

Selank is a synthetic heptapeptide created in the 1990s at the Institute of Molecular Genetics of the Russian Academy of Sciences.  It was engineered as an analog of the endogenous tetrapeptide tuftsin (threonine, lysine, proline, arginine), a peptide fragment linked to immune signaling. To this tuftsin-like core, Selank includes an added Pro–Gly–Pro fragment at the C-terminus. This structural addition is commonly described as improving the peptide’s functional access to the central nervous system (CNS), especially when the compound is administered intranasally. [1, 2]

In practical terms, Selank also has different properties compared to tuftsin, as it no longer has any immune effects. Instead, it is positioned as a peptide that can influence CNS processes without needing oral absorption, and it is most often sold as a nasal spray or nasal drops. From a clinical perspective, Selank is classified as an anxiolytic peptide drug with nootropic properties. It was approved for use in generalized anxiety disorder (GAD) by the Russian Federation Ministry of Health in 2009. The marketed product is Selank® 0.15% (Market Authorization Number LRS-003338/09 of 30.04.2009). 

The development program included research work and clinical trials that continued up to 2009, when the product was introduced to the market under the Selank® 0.15% brand name. It is produced by Peptogen Inc. in a GMP-compliant manufacturing facility. Beyond its approved anxiolytic indication, Selank has been investigated in preclinical models for additional CNS-related effects. These include changes linked to perceived stress and cognitive performance, with several murine studies reporting improvements in memory-related endpoints. 

Selank is marketed in Russia as an intranasal anxiolytic, and most of the human evidence base comes from short courses in people with anxiety disorders:

In a noninferiority trial including 62 patients diagnosed with generalized anxiety disorder (GAD), intranasal Selank was reported to:

Another clinical study in 60 adults with anxiety disorders reported that a 14-day course of intranasal Selank produced the following [4]:

Across the available studies, Selank’s “nootropic” label is mostly tied to cognition under stress or during anxiolytic therapy, rather than large effects in healthy people. 

In a study of 70 participants with anxiety disorders, researchers compared phenazepam alone versus phenazepam combined with Selank and report the following:

Unfortunately, additional human data on the nootropic effects of Selank is scarce. In one rat experiment, a single Selank injection (300 mcg/kg) led to the following observations:

Another animal study in rats with impaired learning compared Selank to piracetam, reporting that Selank improved learning after a single dose and that repeated dosing over several days further strengthened performance, in that model exceeding piracetam’s effect.

Claims around neuroprotection and immune effects come mainly from animal models and a smaller set of clinical immune readouts. 

One preclinical study assessed Selank in outbred rats exposed to long-term ethanol intake, where 10% ethanol served as the only fluid source for 30 weeks and reported the following:

Human data are more limited but point in a similar direction. A clinical report described reduced IL-6 gene expression in peripheral blood after 14 days of intranasal Selank in patients with depression. The report noted a shift in Th1/Th2 cytokine balance in people with GAD toward a more favorable ratio, consistent with immunomodulatory activity in stress-related disorders [9].

In the late 1970s, the USSR Ministry of Defense reportedly commissioned research into agents that could help maintain calm, decision-making capacity, and sustained attention in high-stakes settings such as missile system operations and air traffic control, where errors under fatigue could have severe consequences.

Work on Selank is associated with Nikolay F. Miasoedov and Igor P. Ashmarin. Miasoedov is a Russian biochemist and biotechnologist linked to the Institute of Molecular Genetics of the Russian Academy of Sciences, with extensive publication and patent activity. Ashmarin was a Soviet and Russian scientist in biochemistry and physiology, affiliated with the Russian Academy of Medical Sciences and Moscow State University, also widely published and recognized with state awards.

Development efforts reportedly began in 1978 and continued through the 1980s, with parts of the work conducted under restricted conditions. During screening at the Zakusov Institute of Pharmacology, multiple candidate molecules were evaluated. One reference compound was tuftsin, a tetrapeptide first described in 1970 at Tufts University (Boston, USA). In humans, tuftsin is generated in the spleen by cleavage of a defined four–amino acid fragment from an immunoglobulin.

In the mid-1990s, tuftsin was reported to show anxiolytic-like effects in experimental animals. Building on this, researchers at the Institute of Molecular Genetics modified the tuftsin sequence by adding three amino acids intended to protect the molecule from rapid degradation and extend its functional exposure, enabling measurable effects on the nervous system.

Clinical development later progressed, and Selank entered pharmacy availability in 2009. It has typically been marketed for intranasal use as drops, a route often used for peptide delivery in this context. Selank’s initial clinical positioning focused on anxiety-related disorders, including states characterized by fear and autonomic symptoms such as tremor, muscle tension, sweating, palpitations, dizziness, and related complaints, with subsequent interest in broader applications.

Selank is commonly described as a neuroactive peptide that can reach the CNS after intranasal administration and influence several signaling systems at once. Most proposed mechanisms come from preclinical experiments, supported by a smaller number of clinical biomarker observations. 

Human safety data for Selank mainly comes from short intranasal courses in anxiety-disorder settings. In the available clinical trials summarized in your materials, intranasal Selank was used at daily doses up to 2700 mcg/day for 14 to 21 days, with reports describing good tolerability and no documented adverse events in those study periods. [3, 5] 

Beyond that timeframe, evidence becomes thin. Long-term safety, repeated cycles, and continuous use have not been well characterized in published clinical work, so any claim of safety beyond a few weeks would be speculative.

Commonly discussed side effects such as hair-loss and GABAergic desensitization are unproven and also remain speculative. With intranasal peptides, side effects can also reflect the delivery route rather than systemic toxicity. The most plausible issues are:

Some sources also raise the possibility of infection or contamination with repeated nasal use, which is a practical handling issue rather than an inherent pharmacologic effect.

Clinical observations suggest Selank can be used alongside established anxiolytics in at least some contexts. 

In the aforementioned trials, Selank was reported to reduce benzodiazepine-type side effects when combined with agents such as phenazepam, including cognitive dulling, sedation-like symptoms, and asthenia, while also supporting the overall anxiolytic effect.

The available clinical data characterize Selank as anxiolytic without typical benzodiazepine-like impairment, and some reports even describe mild psychostimulant or antiasthenic effects rather than sedation.

On that basis, Selank is less likely to cause the obvious drowsiness and dizziness that commonly interfere with driving in benzodiazepine use. However, individual responses vary, and anxiety reduction itself can sometimes feel calming in a way that affects vigilance, especially early in use. A practical, evidence-consistent approach is to treat the first doses as a self-assessment period and avoid driving until you know how you respond.

The strongest caution is simply that alcohol is a CNS-active substance that can impair coordination, reaction time, and judgment on its own. Because Selank is proposed to influence inhibitory and mood-related pathways (GABAergic tone, serotonin metabolism, endogenous opioid peptides), combining it with alcohol could plausibly change subjective effects in unpredictable ways, even if Selank is not described as sedating in short trials. For a safety-forward interpretation of the available data, alcohol should be avoided during the dosing period.

Selank is sold as nasal drops because intranasal delivery can provide direct access from the nasal cavity toward the CNS. This may improve CNS exposure for small peptides while avoiding gastrointestinal breakdown and first-pass liver metabolism. Therefore, Selank can be administered intranasally at relatively small doses and still exert positive effects. 

For GAD therapy, Selank is marketed as 0.15% nasal drops, and a commonly cited regimen is two drops (75 mcg per drop) three times daily for up to 14 days, totaling 450 mcg/day, followed by a 1 to 3 week break before another 14-day course. [17] Clinical trials have also used higher dosing, up to 900 mcg per dose given three times daily for 21 days. [5] 

As a practical research reference, some authors suggest mirroring Selank-style cycling, up to 2 weeks on then 1 to 3 weeks off, to limit a theoretical risk of GABA-system desensitization, although this has not been confirmed in studies.

In addition to the marketed Selank formulation, two modified versions are commonly discussed in research-chemical contexts: N-Acetyl Selank and N-Acetyl Selank Amidate. 

Both are based on the same heptapeptide backbone as Selank, but they alter the peptide ends to change how quickly it is broken down:

The key limitation is evidence. Selank has had an approved medical use for GAD since 2009 and has been explored for nootropic, neuroprotective, and immunomodulatory effects. By contrast, N-Acetyl Selank Amidate has little to no direct preclinical or clinical literature, so any claimed benefits are usually inferred from Selank plus the assumption that added stability may improve pharmacokinetics. For that reason, these modified forms are typically sold as research chemicals for educational and experimental purposes, not as approved therapeutics.

If stored correctly, an opened bottle can typically be used for up to 6 months. Keep the bottle tightly closed and store it in a refrigerator at below 10°C (50°F).

Because the formulation contains a preservative, manufacturer information commonly allows short-term storage after opening at room temperature below 25°C (77°F) for up to 30 days. For anything longer than that, refrigeration is preferred. Unopened product shelf life is typically up to 2 years when stored as directed.

Selank formulations often include methylparaben (about 0.01%) as a preservative, which helps maintain stability during normal handling.

If the product stays roughly within 10°C to 25°C (50°F to 77°F) during shipping, meaningful degradation is less likely over typical transit times. That said, prolonged heat exposure is best avoided.

Selank is designed for nasal mucosa contact, not to be swallowed or to run into the throat. A common labeled regimen for Selank 0.15% is two drops (75 mcg per drop) three times daily for up to 14 days (total 450 mcg/day), followed by a 1–3 week break before another course if needed.

Practical technique matters:

You can find the full instructionn for use here.

Onset can vary. Some sources describe effects in minutes in acute stress states, while in established anxietydisorders,s a noticeable change may take several days of regular use. Individual response differs.

Selank has been positioned for short courses during periods of heightened stress and anxiety. If used for this purpose, keep to short regimens (for example, up to 14 days) and avoid extending use beyond studied durations unless guided by a clinician.

Peptogen is the manufacturer behind two of the best-known peptide products in this category, Semax and Selank. When we assess a manufacturer, we focus on traceability, production standards, and quality-control practices rather than marketing claims.

Peptogen Innovation Center is a Russia-based company focused on peptide drugs intended for conditions involving the central nervous system. The company was founded in 2005 with participation from the Institute of Molecular Genetics of the Russian Academy of Sciences, with the stated goal of commercializing institute-developed medicines and advancing in-house peptide programs. The company carries out wholesale deliveries of products through leading national and regional distributors throughout Russia, such as PROTEK and KATREN.

Peptogen reports GMP-aligned manufacturing and describes production in controlled clean-room environments designed to limit particulate and microbial contamination. In typical sterile nasal-drop manufacturing, this includes controlled airflow and pressure differentials, gowning procedures, segregated material transfer, and in-process checks during filling, labeling, and packaging, followed by batch release only after analytical confirmation.

A standard GMP quality system relies on batch documentation, physicochemical testing (identity, purity, concentration), and microbiological controls (sterility or bioburden, endotoxin where relevant). Peptogen describes laboratory-based quality control as part of release, supported by periodic equipment verification and calibration.

Selank is not approved by the U.S. FDAfor ther treatment of anxiety or any other medical indication, which primarily means it has not gone through the FDA’s drug-approval pathway with the required package of clinical efficacy and safety data for a labeled U.S. indication. In addition, the FDA has published safety-risk summaries for compounded products containing selank acetate, highlighting concerns such as immunogenicity risk and uncertainty due to limited human safety information for proposed routes of administration.

Regulatory status and import rules vary by country. “Not approved” is not the same thing as “scheduled,” but it does mean Selank is not available as an authorized prescription medicine through routine pharmacy channels in many jurisdictions. Because enforcement and customs policies differ, any purchase or import should be checked against local rules and, where relevant, medical supervision

If you are choosing between Selank and Semax, it helps to separate what they are marketed for and what their clinical positioning implies. Both are peptide-based products produced by Peptogen and are commonly used intranasally, but they are associated with different primary effects.

Selank is positioned primarily as an anxiolytic with additional nootropic and antiasthenic features reported in some studies. In practical terms, it is most often chosen when the main goal is reduced anxiety and stress-related tension, with possible secondary benefits on cognition under stress.

Semax is positioned primarily as a cognition-oriented peptide, with a profile that is described as more activating in terms of mental performance, attention, and learning-related tasks. It is more often chosen when the goal is improved focus and mental work capacity rather than relaxation.

Because they act through different CNS pathways in the available descriptions, some users consider using them in the same period. However, “not contraindicated” is not the same as “proven safe together.” There is limited direct research on combined use, so combining them should be approached conservatively, especially in people prone to insomnia, agitation, or sensitivity to CNS-active compounds.

Also read our Reviwes of Noopept, Phenylpiracetam, or Meldonium.